IP Library Granted Patent US 11,918,609
Granted Patent B2
US 11,918,609 · App. 17/222,460 · Granted Mar 5, 2024

Stem cells for wound healing

Inventors: Aernout Luttun (Zwevezele, BE); Robert J. Deans (Riverside, CA)
Assignees: ABT HOLDING COMPANY; KATHOLIEKE UNIVERSITEIT LEUVEN
A61K35/28A61K35/12A61P17/02C12N5/0607A01K2207/12A01K2227/105A01K2267/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,918,609
App. No.
17/222,460
Granted
Mar 5, 2024
Kind
B2
Abstract

The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.

Claims (15)

1. A method to promote cutaneous burn healing in a subject by administering cells (I) in an effective amount and for a time sufficient to promote the cutaneous burn healing, wherein the cells (I) are not delivered from a functionalized substrate, wherein the cells (I) are non-embryonic non-germ cells that express CD90 and oct4 or telomerase, are not transformed, are not tumorigenic, and have a normal karyotype.

2. The method of claim 1 , wherein the cells (I) express telomerase.

3. The method of either of claim 1 or 2 , wherein the cells (I) can differentiate into at least one cell type of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

4. The method of claim 3 , wherein the cells (I) can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages.

5. The method of claim 1 , wherein the burn is of the skin and underlying tissues.

6. The method of either of claim 1 or 2 , wherein the cells (I) are not genetically manipulated.

7. The method of either of claim 1 or 2 , wherein the cells (I) are derived from bone marrow.

8. The method of either of claim 1 or 2 , wherein the cells (I) are derived from a human.

9. The method of either of claim 1 or 2 , wherein the subject is human.

10. The method of either of claim 1 or 2 , wherein the cells (I) are administered to the burn topically.

11. The method of either of claim 1 or 2 , wherein the cells (I) are delivered subcutaneously.

12. The method of either of claim 1 or 2 , wherein the cells (I) are administered to the burn by injection.

13. The method of either of claim 1 or 2 , wherein the cells (I) are administered in liquid cell suspension.

14. The method of either of claim 1 or 2 , wherein the cells (I) are administered to the burn using a reservoir.

15. The method of either of claim 1 or 2 , wherein the cells (I) are allogeneic.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →
Continuity (3)
Continuation 15043171 · Feb 12, 2016
Provisional Application 62281334 · Jan 21, 2016
Related Publication 20220031756A1 · Feb 3, 2022